Articles by Elizabeth Budde, MD, PhD
Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discuss the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL.
Practice Patterns and Real Use of Epcoritamab and Glofitamab
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discuss the role of odronextamab.
Bispecific therapy – management of long-term adverse events in the community setting
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Bispecific therapy – treatment setting and management of short-term adverse events
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Management of CRS and ICANS with CAR T-cell Therapy
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discuss the incidence, severity, and management of AEs associated with CAR Tcell therapy.
Risk of Secondary Malignancies in Heavily Pre-Treated Population
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discuss risk of secondary malignancies in heavily pre-treated populations.
Current Approach to Bridging Therapy in R/R DLBCL
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discusses their individual approaches to bridging therapy in R/R DLBCL for patients eligible for CART
Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discuss current challenges for use of CAR T in R/R DLBCL.
Panel Discuses Use of CD19 Bispecifics in Sequencing
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Bradley Hunter, MD, and Fred Locke, MD, and Elizabeth Budde, MD, PhD, share insights surrounding treatment considerations for CD19 targeting.
Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Dr Hunter discusses the decision making process around second-line therapies for transplant-ineligible patients, and further key clinical study data.
Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Multiple studies analyzing considerations for transplant-ineligible patients receiving second-line treatment with CAR T-cell therapy are discussed by key opinion leaders.
Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center An examination of results from key studies in the DLBCL landscape are conducted by Dr Fred Locke.
Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Medical experts from various prestigious oncology institutions drive a conversation around referral patterns in the DLBCL treatment landscape.
Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Medical experts highlight second-line options for treating patients with DLBCL.
Future Outlooks in the Treatment of R/R DLBCL
BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.
Additional Data Updates from ASH 2023
BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD Jason Westin, MD, and expert panelists highlight additional clinical data presented at the 2023 American Society of Hematology annual meeting.
Treatment Sequencing of Later Line Therapies in R/R DLBCL
BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD With the emergence of newer agents, panelists discuss their approaches to best sequence treatments for patients with R/R DLBCL.
R/R DLBCL: Safety Considerations for Bispecific Antibodies
BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD A comprehensive overview of safety considerations for bispecific antibodies in patients treated for R/R DLBCL.
Bispecifics for Third Line Therapy of R/R DLBCL
BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.
Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting
BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD Focusing their discussion on therapeutic options for patients with R/R DLBCL, in the third line and beyond setting.
Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL
BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.
Clinical Perspectives of CAR T in R/R Diffuse Large B-Cell Lymphoma
BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD Experts share clinical perspectives on the use of CAR T for patients with DLBCL, in the R/R setting.
Data Updates: CAR T in the ZUMA-7 and TRANSFORM Trials for R/R DLBCL
BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD Focused discussion on the latest updates of CAR Ts such as axi-cel and liso-cel from the ZUMA-7 and TRANSFORM trials, respectively.
The Role of CAR T-Cell Therapy in R/R DLBCL
BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD Centering discussion on the role of CAR T-cell therapy for patients with R/R DLBCL.
Real-World Outcomes of Tafasitamab-Lenalidomide for Patients with R/R DLBCL
BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD Panelists consider real-world outcomes for treating patients with tafasitamab-lenalidomide for R/R DLBCL.
Tafasitamab and Lenalidomide for R/R DLBCL
BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD A comprehensive overview of tafasitamab plus lenalidomide for patients with relapsed/refractory DLBCL, highlighting data updates and the impact on clinical practice.
Treatment Selection in Second Line R/R DLBCL
BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD Expert perspectives on treatment selection for patients with R/R DLBCL receiving second line therapy.
Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL
BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD A brief discussion on evolving practice standards and clinical perspectives that help to inform selection of best therapy for patients with DLBCL that progress beyond initial therapy.
Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices
Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma
How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients